Email UpdatesProminent Reports
Presents aspirin therapy recommendations for adults 40-59 years old with a >=10% 10-Year CVD risk score
Artifact Creation and Usage
This artifact was developed by MITRE software engineers and clinical informaticists, in collaboration with clinical subject matter experts and leaders from the U.S. Preventive Services Task Force (USPSTF).
Additional information about the USPSTF's preventive health expertise is available here.
Additional information about MITRE's health expertise is available here.
If you would like further information, would like to give us feedback, or have any questions about this artifact, please contact us at ClinicalDecisionSupport@ahrq.hhs.gov.
Copyright is held by U.S. Preventive Services Task Force and administered by AHRQ.
Semi-structured text that describes the recommendations for implementation in CDS
Provides an evidence-based recommendation for low dose aspirin therapy to mitigate a 40-59 year old patient's elevated risk of developing CVD
This artifact applies to adults aged 40 to 59 years with a =>10 year CVD risk
This artifact is intended to be used by providers while delivering care in an outpatient setting
A new and significantly changed recommendation was published by the U.S. Preventive Services Task Force on April 26, 2022. This CDS Connect artifact reflects the new recommendation.
Note that a Grade D recommendation (U.S. Preventive Services Task Force recommends against initiating low-dose aspirin for individuals aged 60 years and older) is not included in this artifact.
Implementation details: The CDS implementer can adjust the age parameters.
This artifact is intended for use in outpatient settings only and should not be used in acute care settings.
Additional information and resources: CDS Connect artifacts are not “standalone” and are not intended to be completely plug-and-play (i.e., healthcare systems will need to integrate each artifact with components of their health information technology (IT) system for the artifact to work). CQL Services, an open source publicly-available tool that facilitates integration of CQL code with a health IT system, can be used by organizations that build out a coded expression of this artifact for pilot implementation in their healthcare organization. CQL Services is available here: https://github.com/AHRQ-CDS/AHRQ-CDS-Connect-CQL-SERVICES. Implementers should conduct extensive testing, including clinical testing in real-life workflows, of all artifacts. It is expected that artifacts will be customized and adapted to local clinical and IT environments.
Derived from the 2022 USPSTF guideline "Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication"
US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577–1584. doi:10.1001/jama.2022.4983 https://jamanetwork.com/journals/jama/fullarticle/2791399
Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;327(16):1585–1597. doi:10.1001/jama.2022.3337 https://jamanetwork.com/journals/jama/fullarticle/2791401
The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit.
Grade C
A full review of the evidence supporting the recommendation can be found here.
Decision notes are included in the Implementation Guide.
- Trigger Type: Data event
- Trigger Event: A new 10-Year CVD risk score is documented in an outpatient setting
| Patient is >=40 and <=59 years of age |
| AND |
| MOST RECENT 10-Year CVD risk score >=10% in the past 6 years |
| Diagnosis of CVD |
| OR currently receiving aspirin (at any dose) |
| OR ordered for or receiving palliative care |
| OR aspirin allergy |
| OR evidence of increased risk of bleeding, represented by: |
| Diagnosis of active gastrointestinal (GI) bleed |
| OR diagnosis of active GI ulcers |
| OR diagnosis of bleeding disorders |
| OR diagnosis of end stage renal disease (ESRD) |
| OR dialysis within the past 7 days |
| OR diagnosis of cirrhosis |
| OR MOST RECENT alanine transaminase (ALT) result is > 150 U/L |
| OR diagnosis of thrombocytopenia |
| OR currently receiving an anticoagulant |
| OR currently receiving non-steroidal anti-inflammatory medications (NSAIDs) |
| OR MOST RECENT systolic blood pressure (SBP) >= 160 millimeters/mercury (mmHg) |
| Interventions | |
NOTIFY clinician that aspirin therapy may be considered.
| |
| DISPLAY link to shared decision making resource. | |
| DISPLAY link to U.S. Preventative Services Task Force guidelines. | |
| DISPLAY link to education materials that are relevant to the patient's plan of care | |
| Actions | |
| REQUEST medication order | |
| DOCUMENT any new medications on the active medication list | |
| DOCUMENT provider response if a reason for not prescribing aspirin is provided |
This artifact has not been tested in a clinical setting.